Synartro is a Swedish life science company developing local injection treatments that provide superior and sustained efficacy without systemic side-effects. This is achieved by chemically binding existing proven drugs to our local injection technology.

The initial focus area is knee osteoarthritis, a disease with significant demand for treatments with improved efficacy and safety profiles for the growing patient population.  

The company is ready to start the clinical phase for the lead compound SYN321 with a phase 1/2a trial in osteoarthritis patients.  

The company is seeking investments to enable continued development of its promising lead program SYN321.

For further information, please get in touch with Magnus Hurst, CFO & Investor Relations.